CLINICAL STUDIES OF COCAINE TOLERANCE, SENSITIZATION AND WITHDRAWAL

拟议的SPIRCAP的这一组成部分描述了两个具体目标：1. 筛选临床上可用的干扰急性脑出血的药物 行为中对可卡因的神经化学和行为反应 微透析和自我给药范例。前景看好的功能 已确定的可卡因拮抗剂随后将在人体内进行评估 实验室研究。2.筛选临床可用的药物疗法 干扰对反复吸食可卡因的敏化反应 行政管理。在戒酒患者中，这样的药物疗法可能会保护 通过防止一次可卡因发作来防止复发依赖 来自产生的虐待，尤其是强烈的主观反应。

This component of the proposed SPIRCAP describes two specific aims: 1. To screen clinically available agents that interfere with the acute neurochemical and behavioral responses to cocaine in behavioral, microdialysis and self-administration paradigms. Promising functional cocaine antagonists identified would subsequently be evaluated in human laboratory studies. 2. To screen clinically available pharmacotherapies that interfere with the sensitized response to repeated cocaine administration. In abstinent patients, such pharmacotherapies may protect against relapse to dependence by preventing a single episode of cocaine abuse from producing and especially intense subjective response.